Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Altavant Sciences

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

    The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront

    The candidate has shown potential in treating B-cell mediated autoimmune diseases

    - PMLiVE

    AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn

    The companies are aiming to develop MGDs for targets across oncology and immunology

    - PMLiVE

    AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

    The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

    - PMLiVE

    Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

    The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

    - PMLiVE

    GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m

    The company plans to develop the candidate for autoimmune diseases such as lupus

    - PMLiVE

    GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

    The companies aim to develop a portfolio of up to ten candidates

    - PMLiVE

    Sanofi and Belharra Therapeutics enter $700m immunological disease collaboration

    The partnership will utilise Belharra’s platform to identify and advance small molecules against immunology targets

    Biogen Idec building

    Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition

    The company will gain access to HI-Bio’s lead asset for immune-mediated and rare diseases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links